Clinical Trials for Mesothelioma Patients: AZD2171

Read about a current clinical trial being conducted to study the effects of AZD2171 for patients who have been diagnosed with mesothelioma. Please note: this information is provided by Weitz & Luxenberg for informational purposes only.

Rationale and Purpose:
AZD2171 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. This phase II trial is studying how well AZD2171 works in treating patients with malignant mesothelioma that cannot be removed by surgery.

Condition:
Malignant Mesothelioma

Intervention:
Drug: Cediranib; Procedures: antiangiogenesis therapy, laboratory biomarker analysis, protein tyrosine kinase inhibitor therapy

Study Description:
Phase, Type and Design: Phase II Interventional Study; treatment, open label

Official Title: Phase II Study of AZD2171 (NSC#732208) in Patients with Malignant Mesothelioma

Recruitment Information: Recruitment Status: Recruiting Enrollment: 50 Start Date: December 2005

Courtesy of ClinicalTrials.gov,

Other helpful links:

Asbestos Asbestos
Asbestos and lung cancer Asbestos and lung cancer
Mesothelioma attorney Mesothelioma attorney
Mesothelioma Lawyer Mesothelioma lawyer
Asbestos attorney Asbestos attorney